| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3263 |
| Trial ID | NCT05641428 |
| Disease | B-Cell Non-Hodgkin's Lymphoma | Diffuse Large B-Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | ARI-0001|Axi-cel|YesCAR-Ta|Axicabtagene Ciloleucel |
| Generation | 2nd |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL |
| Year | 2022 |
| Country | Netherlands |
| Company sponsor | University Medical Center Groningen |
| Other ID(s) | HO161|2021-000937-15 |
| Vector information | |||||
|
|||||
| Cohort1: ARI-0001 | |||||||||
|
|||||||||
| Cohort2: Axi-cel | |||||||||
|
|||||||||